Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01041716 · ClinicalTrials.gov registry record
Clinical and Microbiological Outcomes of Infections Due to Carbapenem-Resistant Gram-Negative Bacteria
A clinical trial of Drug Resistance, Microbial, sponsored by Maimonides Medical Center.
- Completed
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT01041716: Completed study of Drug Resistance, Microbial, sponsored by Maimonides Medical Center.
NCT01041716 is a study of Drug Resistance, Microbial that has completed, run by Maimonides Medical Center. The registered enrollment target is 300 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01041716, a study of Drug Resistance, Microbial, has completed, sponsored by Maimonides Medical Center.
- COMPLETED
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
Carbapenems are a class of antibiotic agents which kill a broad spectrum of bacteria. Infections due to gram-negative bacteria which have acquired resistance to carbapenems are increasing, especially with Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa . The optimal treatment of such infections is not known. Antibiotics like polymyxin, tigecycline and rifampin are used alone or in combination with other antibiotics. The outcome of using these new and old drugs is not well studied. This observational study aims to study the clinical and microbiological outcomes of these infections and treatment at our institution.
Primary Outcome
Resolution (or improvement) of clinical symptoms and signs of infection and discontinuation of the antibiotics.
Conditions Studied
Interventions
- OTHER None - Observational study
Study Locations (1)
New York
- Maimonides Medical Center - Brooklyn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2009-12 |
| Est. Completion | 2010-12 |
What the finished NCT01041716 record still lists
NCT01041716 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Drug Resistance, Microbial appearing as the primary indexed condition, and to 1 intervention - of which None - Observational study is the first listed.
NCT01041716 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01041716 about?
NCT01041716 is a clinical study titled "Clinical and Microbiological Outcomes of Infections Due to Carbapenem-Resistant Gram-Negative Bacteria". Carbapenems are a class of antibiotic agents which kill a broad spectrum of bacteria. Infections due to gram-negative bacteria which have acquired resistance to carbapenems are increasing, especially with Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa . The optimal treatme...
What is the current status of trial NCT01041716?
This trial is currently completed. The enrollment target is 300 participants. The study started on 2009-12. Estimated completion is 2010-12.
What conditions does trial NCT01041716 study?
This clinical trial studies the following conditions: Drug Resistance, Microbial.
What interventions are being tested in trial NCT01041716?
The interventions under investigation include: None - Observational study (OTHER).
Who is sponsoring clinical trial NCT01041716?
This trial is sponsored by Maimonides Medical Center, which has 39 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01041716 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia